4.7 Article

Hepatitis C virus and cumulative infections are associated with atherogenic cardiovascular events in HIV-infected subjects

Journal

ANTIVIRAL RESEARCH
Volume 169, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.antiviral.2019.05.016

Keywords

Infection; Atherosclerosis; Hepatitis C; HIV

Funding

  1. Instituto de Salud Carlos III [PI12/02283, PI16/00684, CPII014/00025, FI14/00431]
  2. Red Tematica de Investigacion Cooperativa en SIDA [RD12/0017/0029, RD16/0025/0020, RD16/0025/0019]
  3. Accion Estrategica en Salud, Plan Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica 2008-2011, Instituto de Salud Carlos III, Fondos FEDER
  4. Consejeria de Salud y Bienestar Social of Junta de Andalucia through the Nicolas Monardes program [C-0032/17]

Ask authors/readers for more resources

Objectives: to analyze the association between HCV coinfection and cumulative infections with the development of a cardiovascular disease in HIV-infected subjects. Methods: HIV-infected subjects attended at Virgen del Rocio University Hospital, between January 1982 and March 2018, were considered if fulfilled the following criteria: at least two visits to the HIV clinic, clinical records with data about VZV reactivation and bacterial infections, available data on HCV coinfection status. Atherogenic cardiovascular events were registered. To analyze factors associated with the development of cardiovascular event, a logistic regression analysis was performed. Results: 823 subjects were included in the study. During the observational period, 58/823 (7.05%) developed a cardiovascular event. Advanced age at HIV-1 diagnosis, a low T-CD4 nadir, HCV coinfection and the burden of infections were independently associated with the risk of developing a cardiovascular event, apart from lipid levels and diabetes. Conclusions: both HCV and the burden of infections are associated with an increased risk of cardivascular event in HIV-infected patients, together with other cardiovascular risk factors. Therapeutic strategies such as HCV erradication or VZV immunization could ameliorate cardiovascular risk in these subjects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available